先健科技漲超7% IBS Angel™鐵基可吸收支架系統獲馬來西亞註冊批准
格隆匯6月10日丨先健科技(1302.HK)一度漲超7%報5.3港元,股價創今年1月以來新高,市值245億港元。先健科技(1302.HK)是醫療器械行業高值耗材領域的龍頭企業之一,公司今日宣佈,其控股子公司元心科技自主研發的創新產品IBS Angel™鐵基可吸收支架系統(“IBS Angel™”)於6月8日獲馬來西亞藥監局MDA頒發的註冊證,成為全球首個商業化的鐵基可吸收血管支架,填補了兒童肺血管狹窄治療的國際空白。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.